CHDI
Listed here are over 1,075 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Aretz J, Jeyasankar G, Salerno-Kochan A, Thomsen M, Thieulin-Pardo G, Haque T, Monteagudo E, Felsenfeld D, Finley M, Vogt TF, Boudet J, Prasad BC
A FAN1 point mutation associated with accelerated Huntington's disease progression alters its PCNA-mediated assembly on DNA
Boareto M, Yamamoto Y, Long JD, Sampaio C, McColgan P, Diack C, Ducray PS
Modeling disease progression and placebo response in Huntington disease: Insights from Enroll-HD and GENERATION HD1 cohorts
Bakels HS, van der Zwaan KF, Van Zwet E, Reijntjes R, Sprenger GP, Knecht TA, Roos RAC, de Bot ST
Comparison of the clinical spectrum of juvenile- and adult-onset Huntington disease: A national cohort and Enroll-HD observational study
Halabi N, Killoran A, Nopoulos PC, Schultz JL
Differentiating hyperkinetic and hypokinetic motor features in the progression of Huntington's disease
Stocksdale JT, Leventhal MJ, Lam S, Xu YX, Wang YO, Wang KQ, Tomas R, Faghihmonzavi Z, Raghav Y, Smith C, Wu J, Miramontes R, Sarda K, Johnson H, Shin MG, Huang T, Foster M, Barch M, Armani N, Paiz C, Easter L, Duderstadt E, Vaibhav V, Sundararaman N, Felsenfeld DP, Vogt TF, Van Eyk J, Finkbeiner S, Kaye JA, Fraenkel E, Thompson LM
Intersecting impact of CAG repeat and huntingtin knockout in stem cell-derived cortical neurons
Jain G, Trombetta-Lima M, Matlahov I, Ribas HT, Chen T, Parlato R, Portale G, Dolga AM, van der Wel PCA
Inhibitor-based modulation of huntingtin aggregation mechanisms mitigates fibril-induced cellular stress
Jain G, Trombetta-Lima M, Matlahov I, Ribas HT, Chen T, Parlato R, Portale G, Dolga AM, van der Wel PCA
Inhibitor-based modulation of huntingtin aggregation mechanisms mitigates fibril-induced cellular stress
Fuller RL, Feigenbaum P, LaPelle N, Sathe S, Dalal P, Vaidya JG, Sinha N, Roché M, Fitzer-Attas CJ, Sampaio C, Stebbins GT
Functional Rating Scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington's disease
Pearl JR, Shetty AC, Cantle JP, Bergey DE, Bragg RM, Coffey SR, Kordasiewicz HB, Hood LE, Price ND, Ament SA, Carroll JB
Altered huntingtin-chromatin interactions predict transcriptional and epigenetic changes in Huntington's disease mouse models
Marchionini DM, De Lombaerde S, van Rijswijk J, Zajicek F, Everix L, Miranda A, Aaltonen MJ, Kluger CM, Wild T, Kakoulidou A, Gundelach J, Fieblinger T, Fentz J, Rosinski J, Obenauer J, Greene JR, Liu L, Munoz-Sanjuan I, Verhoye M, Verhaeghe J, Bard J, Staelens S, Bertoglio D
Pharmacodynamic biomarkers responsive to mutant huntingtin lowering in a Huntington's disease mouse model
Ling S, Zhang X, Dai Y, Jiang Z, Zhou X, Lu S, Qian X, Liu J, Selfjord N, Satir TM, Lundin A, Touza JL, Firth M, Van Zuydam N, Bilican B, Akcakaya P, Hong J, Cai Y
Customizable virus-like particles deliver CRISPR-Cas9 ribonucleoprotein for effective ocular neovascular and Huntington's disease gene therapy
Abeyasinghe PM, Cole JH, Razi A, Poudel GR, Paulsen JS, Tabrizi SJ, Long JD, Georgiou-Karistianis N
Brain age as a new measure of disease stratification in Huntington's disease
Justice JL, Greco TM, Hutton JE, Reed TJ, Mair ML, Botas J, Cristea IM
Multi-epitope immunocapture of huntingtin reveals striatum-selective molecular signatures
Rodríguez Santana I, Frank SA, Mestre TA, Arnesen A, Hamilton JL, Hubberstey H, Winkelmann M, Hernandez-Jimenez E, Frimpter J, Dolmetsch R, Ali TM
Suicidal ideation and sleep disturbances among people with Huntington disease: Evidence from the HDBOI study
Wang N, Zhang S, Langfelder P, Ramanathan L, Gao F, Plascencia M, Vaca R, Gu X, Deng L, Dionisio LE, Vu H, Maciejewski E, Ernst J, Prasad BC, Vogt TF, Horvath S, Aaronson JS, Rosinski J, Yang XW
Distinct mismatch-repair complex genes set neuronal CAG-repeat expansion rate to drive selective pathogenesis in HD mice
Mätlik K, Pressl C, Heintz N
Cell type-specific studies of human tissue for investigation of the molecular cell biology of late-onset neurodegenerative disease
Wu Q, Yao M, Liu H, Kakazu A, Ouyang Y, Liu C, Li R, Yang F, Wang A, Surasinghe S, Gerochi D, Baldo B, Jahn S, Tang H, Lu H, Wei Z, Duan W
Progressively reduced cerebral oxygen metabolism and elevated plasma NfL levels in the zQ175DN mouse model of Huntington's disease
Olson L, Dickens S, Schultz JL, Neema M, Nopoulos PC
No evidence of early developmental delay in juvenile-onset Huntington's disease patients
Scahill RI, Farag M, Murphy MJ, Hobbs NZ, Leocadi M, Langley C, Knights H, Ciosi M, Fayer K, Nakajima M, Thackeray O, Gobom J, Rönnholm J, Weiner S, Hassan YR, Ponraj NKP, Estevez-Fraga C, Parker CS, Malone IB, Hyare H, Long JD, Heslegrave A, Sampaio C, Zhang H, Robbins TW, Zetterberg H, Wild EJ, Rees G, Rowe JB, Sahakian BJ, Monckton DG, Langbehn DR, Tabrizi SJ
Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington's disease decades before clinical motor diagnosis
Stocksdale JT, Leventhal MJ, Lam S, Xu YX, Wang YO, Wang KQ, Tomas R, Faghihmonzavi Z, Raghav Y, Smith C, Wu J, Miramontes R, Sarda K, Johnson H, Shin MG, Huang T, Foster M, Barch M, Armani N, Paiz C, Easter L, Duderstadt E, Vaibhav V, Sundararaman N, Felsenfeld DP, Vogt TF, Van Eyk J, Finkbeiner S, Kaye JA, Fraenkel E, Thompson LM
Intersecting impact of CAG repeat and Huntingtin knockout in stem cell-derived cortical neurons
Gil-Salcedo A, Lunven M, Jacquemot C, Massart R, Bachoud-Levi AC
Specific contribution of cognitive and motor impairments with functional capacity and dependence in Huntington's disease
Yablonska S, Strohlein CE, Baranov SV, Yeh SM, Patel A, Singh T, Jauhari A, Kim J, Khattar NK, Li F, Wang X, Chang YF, Lee CYD, Yang XW, Carlisle DL, Friedlander RM
Regulation of mutant huntingtin mitochondrial toxicity by phosphomimetic mutations within its n-terminal region
Bunting EL, Donaldson J, Cumming SA, Olive J, Broom E, Miclăuș M, Hamilton J, Tegtmeyer M, Zhao HT, Brenton J, Lee WS, Handsaker RE, Li S, Ford B, Ryten M, McCarroll SA, Kordasiewicz HB, Monckton DG, Balmus G, Flower M, Tabrizi SJ
Antisense oligonucleotide-mediated MSH3 suppression reduces somatic CAG repeat expansion in Huntington's disease iPSC-derived striatal neurons
Handsaker RE, Kashin S, Reed NM, Tan S, Lee WS, McDonald TM, Morris K, Kamitaki N, Mullally CD, Morakabati NR, Goldman M, Lind G, Kohli R, Lawton E, Hogan M, Ichihara K, Berretta S, McCarroll SA
Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease
Xu H, Ajayan A, Langen R, Chen J
Pleiotropic effects of mutant huntingtin on retinopathy in two mouse models of Huntington's disease
Khetarpal V, Herbst T, Dominguez C, Munoz-Sanjuan I, Sampaio C, Marks B, Miller D, Farnham J, Ledvina A, Anglehart H, Rehmani I, LaFayette A, Spridco N, Langbehn D, Wild EJ, Pacifici R
Lack of evidence for kynurenine pathway dysfunction in Huntington’s disease: Cerebrospinal fluid and plasma analyses from the HDClarity study
Mouro Pinto R, Murtha R, Azevedo A, Douglas C, Kovalenko M, Ulloa J, Crescenti S, Burch Z, Oliver E, Kesavan M, Shibata S, Vitalo A, Mota-Silva E, Riggs MJ, Correia K, Elezi E, Demelo B, Carroll JB, Gillis T, Gusella JF, MacDonald ME, Wheeler VC
In vivo CRISPR-Cas9 genome editing in mice identifies genetic modifiers of somatic CAG repeat instability in Huntington's disease
van der Zwaan KF, Feleus S, Dekkers OM, Roos RAC, de Bot ST
Total functioning capacity scale in Huntington's disease: natural course over time
Stimming EF, Claassen DO, Sen GP, Klepitskaya O, Serbin M, Kim H, Hinton SC, Haubenberger D
Longitudinal treatment patterns of chorea in North American patients with Huntington's disease: Data from Enroll-HD
Maestri S, Scalzo D, Damaggio G, Zobel M, Besusso D, Cattaneo E
Navigating triplet repeats sequencing: concepts, methodological challenges and perspective for Huntington's disease
Cattaneo E, Scalzo D, Zobel M, Iennaco R, Maffezzini C, Besusso D, Maestri S
When repetita no-longer iuvant: somatic instability of the CAG triplet in Huntington's disease
Feleus S, Vo MTD, Kuijper LCM, Roos RAC, de Bot ST
Cognitive impairment predicts medication discrepancies in Huntington's disease: patient self-report compared to pharmacy records
Schultz JL, Ogilvie AC, Harshman LA, Nopoulos PC
β-blocker use and delayed onset and progression of Huntington disease
Bagherpoor Helabad M, Matlahov I, Kumar R, Daldrop JO, Jain G, Weingarth M, van der Wel PCA, Miettinen MS
Integrative determination of atomic structure of mutant huntingtin exon 1 fibrils implicated in Huntington disease
Akkermans J, Miranda A, Verhaeghe J, Elvas F, Zajicek F, Bard J, Liu L, Khetarpal V, Doot R, Staelens S, Bertoglio D
Biodistribution and dosimetry of the PET radioligand [18F]CHDI-650 in mice for detection of mutant huntingtin aggregates
Feleus S, Skotnicki LEM, Roos RAC, de Bot ST
Medication use and treatment indications in Huntington's disease; analyses from a large cohort
Everix L, Elvas F, Miranda Menchaca A, Khetarpal V, Liu L, Bard J, Staelens S, Bertoglio D
Preclinical validation and kinetic modelling of the SV2A PET ligand [18F]UCB-J in mice
Zajicek F, Verhaeghe J, De Lombaerde S, Van Eetveldt A, Miranda A, Munoz-Sanjuan I, Dominguez C, Khetarpal V, Bard J, Liu L, Staelens S, Bertoglio D
Preclinical evaluation of the novel [18F]CHDI-650 PET ligand for non-invasive quantification of mutant huntingtin aggregates in Huntington's disease
Sampaio C
FDA boosts the progressive supranuclear palsy rating scale!
Sogorb-Gonzalez M, Landles C, Caron NS, Stam A, Osborne G, Hayden MR, Howland D, van Deventer S, Bates GP, Vallès A, Evers M
Exon 1-targeting miRNA reduces the pathogenic exon 1 HTT protein in Huntington disease models